EC Approves Ofatumumab Combo in Relapsed CLL

13 Dicembre 2016 – The European Commission (EC) has approved ofatumumab in combination with fludarabine and cyclophosphamide as a treatment for adult patients with relapsed chronic lymphocytic leukemia (CLL), according to Genmab, which codevelops the anti-CD20 antibody with Novartis. The approval, which followed a positive recommendation from the Committee for Medicinal Products for Human Use, was based on data from the phase III COMPLEMENT-2 … (leggi tutto)